Electromed (ELMD) Q4 2024 earnings summary

Executive summary

• Achieved record quarterly and annual revenues, with Q4 net revenue of $14.8M (up 9% YoY) and full-year revenue of $54.7M (up 14% YoY), alongside record operating and net income for both Q4 and FY24.

• Operating income reached $2.3M for Q4 (up 56.3%) and $6.6M for the year (up 64.2%).

• Strong cash position at $16.1M, no debt, and working capital of $36.5M at fiscal year-end.

• Expanded sales force and commercial leadership, with 53 sales reps at year-end and plans to reach 57 in FY25.

• Gained market share through infrastructure investments and market development initiatives, despite headwinds from the expiration of the CMS waiver.

Financial highlights

• Direct home care segment revenue grew 12.6% YoY to $49.5M, representing 90% of total revenue.

• Hospital revenue increased 21.9% YoY to $2.5M; home care distributor revenue rose 14.5% to $1.9M.

• Gross profit was $41.7M (76.3% margin), up from $36.5M (76% margin) last year; Q4 gross margin was 76.2%.

• Net income for FY24 was $5.2M ($0.58/diluted share), up 62.7% from $3.2M ($0.36/diluted share) in FY23.

• SG&A expenses increased 9.2% to $34.5M, mainly due to higher compensation and sales support.

Outlook and guidance

• Expectation to expand sales team to 57 reps and increase home care revenue per rep to $900K–$1M in FY25.

• Management anticipates continued double-digit top-line growth and expanded operating leverage, supported by ongoing investments in growth and market development.